Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02978716
Title Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors G1 Therapeutics, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | SVN | SVK | HRV | BGR | BEL


No variant requirements are available.